Cilta-cel Induces Universal MRD Negativity in High-Risk Smoldering Multiple Myeloma

The management of high-risk smoldering multiple myeloma remains a significant clinical challenge, as these patients face a high probability of progression to symptomatic end-organ damage, often characterized by the CRAB criteria of calcium elevation, renal insufficiency, anemia, and bone lesions [1, 2]. While quadruplet-based induction regimens and autologous stem cell transplantation have improved outcomes in newly diagnosed cases, these intensive approaches are not curative, and nearly all patients eventually relapse [2, 3]. Recent advances in B-cell maturation antigen (BCMA) directed therapies, including bispecific antibodies and chimeric antigen receptor T-cell (CAR T) products, have transformed the treatment of relapsed or refractory disease [4, 5]. However, the efficacy of these immunotherapies in later lines is often limited by T-cell exhaustion (a state of T-cell dysfunction resulting from chronic antigen exposure) and the increasing genomic complexity of the tumor [6, 7]. Researchers are now investigating whether utilizing these potent agents during the precursor stage, when the patient's immune fitness is more preserved, can achieve deeper and more durable responses [8, 7].